Close Menu

NEW YORK — Cancer Genetics on Thursday posted a nearly 24 percent year-over-year decline in revenues for the third quarter as the SARS-CoV-2 pandemic impacted its customers' R&D operations.

For the three-month period ended September 30, Cancer Genetics' revenues fell to $1.6 million from $2.1 million a year earlier as customers for its drug-discovery and preclinical oncology services experienced shifted their resources to SARS-CoV-2 initiatives and their scientific and discovery teams began working remotely.          

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Sponsored by

Diverse components of the UC Davis campus have been mobilized to deploy HTP testing to provide a safe working environment and keep the pandemic under control.